Background: Abiraterone acetate (AA) is a selective inhibitor of CYP17 and showed to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel in the COU-AA-301 trial. AA is not widely available for patients treated at the public health system (SUS) and real-life data regarding this treatment in Brazil are lacking. This study aims to describe the epidemiological profile and outcomes of patients diagnosed with mCRPC who progressed after docetaxel treated with AA in a Brazilian public health institution. Methods: We retrospectively reviewed clinical data of patients with mCRPC who progressed after docetaxel and were treated with AA (1000mg/d PO) plus prednisone (5mg/BID PO) from January 2015 to December 2016 in our instituition. Patient demographic and clinical characteristics were described using summary statistics. Kaplan-Meyer method was used to estimate OS and time to prostate-specific antigen (PSA) progression for AA treatment. Results: 37 patients were included for analysis. Median age was 71 yo. Median PSA at AA start was 57 ng/mL (range 0.10-6,676.00), Gleason score was > 7 in 59.5% and ≤7 in 32.4%. 75.7% of patients had symptomatic bone metastasis requiring opioids. At a median follow up of 68 months, the median duration of treatment was 5 months with a median OS of 13 months and a median time to PSA progression of 4 months. Gleason score did not correlate with outcomes (p = 0.56). Although patients who had a prior hormone therapy (PHT) > 12mo had better OS (15mo) when compared to those with PHT < 12 (10mo), this difference was not statistically significant (p = 0.26). AA was well tolerated and disease progression was the main reason for AA discontinuation (86.8%). Conclusions: This analysis shows that AA is an effective and safe treatment option for patients in public health system in a developing country, with comparable outcomes to COU 301 trial in OS, showing benefits regardless Gleason and PHT status. These patients did not receive later lines of treatment, and this could have impacted OS in this study. The incorporation of AA in the SUS should be considered.